Home

Volker Knappertz

CIK 1754122 · EVP, Research and Development · last filed 2024-02-29

Volker Knappertz is an EVP, Research and Development who has filed 22 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing shows the insider sold $30.1K of AUPH on Feb 29, 2024. Across all open-market trades the lifetime net is −$1.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.13M

Companies

2

Total Filings

22

Lifetime Open-Market Net

-$1.26M

Filer Profile

Reported Address
SOVEREIGN HOUSE, VISION PARK, HISTON
CAMBRIDGE, X0 CB249BZ
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AUPH EVP, Research and Development 319,128 $16.08 $5.13M -$167.9K 4 2024-02-29
GW PHARMACEUTICALS PLC (GWPH) Delisted Chief Medical Officer 92,412 $218.96 $20.23M -$1.09M 17 2021-03-30

Recent Filings

22 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-02-29 AUPH Sell (S) −4,930 -$30.1K EDGAR
2024-02-22 AUPH Sell (S) −25,146 -$137.8K EDGAR
2023-03-06 AUPH Grant (A) +191,462 $0 EDGAR
2022-08-01 AUPH Grant (A) — $0 EDGAR
2021-05-07 — Disp (D) −92,412 $0
2021-03-30 GW PHARMACEUTICALS PLC (GWPH) Delisted Sell (S) −3,060 -$55.4K EDGAR
2021-03-02 GW PHARMACEUTICALS PLC (GWPH) Delisted Mixed +77,532 -$900.6K EDGAR
2021-02-24 GW PHARMACEUTICALS PLC (GWPH) Delisted Grant (A) — $0 EDGAR
2021-01-20 GW PHARMACEUTICALS PLC (GWPH) Delisted Sell (S) −6,000 -$70.0K EDGAR
2020-11-25 GW PHARMACEUTICALS PLC (GWPH) Delisted Sell (S) −12,000 -$126.0K EDGAR
Showing 1–10 of 22
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.